Some codeine behind the counter Down Under
This article was originally published in The Tan Sheet
Australia's Therapeutic Goods Administration moves codeine-containing nonprescription painkillers from OTC sales to pharmacy only, but leaves cough and cold preparations with the ingredient on store shelves. TGA's National Drugs and Poisons Schedule Committee in June voted to switch codeine products labeled for 100-mg daily dose limit, with no more than 12 mg in individual doses, starting in May 2010 from schedule 2 - nonprescription sales without pharmacist intervention - to schedule 3, which requires distribution by pharmacists. The committee also set a maximum package size of five days' supply for codeine painkillers and for cough/cold preparations labeled for 60-mg maximum daily dose, with no more than 10 mg in each dose. The change follows concerns about codeine abuse, and the committee noted requiring customers to ask pharmacists for the products would help curb inappropriate use. In the U.S., FDA classifies all codeine products as Rx only, while in other countries, including Australia, some drugs containing the ingredient are available OTC or from pharmacists without prescription
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.